Login to Your Account

Orchard raises $113.5M series B as gene therapy begins to bear fruit

By Nuala Moran
Staff Writer

Tuesday, December 19, 2017

LONDON – Orchard Therapeutics Ltd. has raised a massive – and oversubscribed – £85 million (US$113.5 million) series B round to fund the commercialization of rare disease gene therapy programs in-licensed from academic labs.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription